Issue 17 - Apr 27, 2018
Issue 16 - Apr 20, 2018
  • Sharpless adds $100 million to NCI’s RPG pool, R01s for young investigators boosted by 25%

    NCI will bump up the budget for its Research Project Grant pool by $100 million in 2018—the largest increase to the institute’s RPG pool since 2003, NCI Director Norman “Ned” Sharpless said at the annual meeting of the American Association for Cancer Research in Chicago.

    “This is possible thanks to increases in the past three years in our congressionally appropriated budget,” Sharpless said in his first public speech as NCI director at the meeting April 16. “While this is not solely for basic science—there are lots of laudable clinical trials and health services research funded from the RPG pool—this is the most straightforward way to assure we continue to fund investigator-initiated basic science.”

  • Piantadosi leaves Cedars-Sinai for Alliance and Harvard

    Steven Piantadosi is moving to Alliance, where he will serve as the associate group chair for strategic initiatives and innovation.

  • In Brief

    • SU2C focuses on precursor conditions in multiple myeloma
    • St. Baldrick’s commits $8 million to SU2C Pediatric Cancer Dream Team
    • Isabella Santos Foundation gives $5 million for rare & solid tumor program at Levine Children’s Hospital
    • MedStar Georgetown offers proton therapy with HYPERSCAN technology for adults and kids with cancer
    • Reprocell and Fox Chase to open biosample repository in India
  • TCCL Logo

  • Clinical Roundup

    • Keytruda combination improved OS regardless of PD-L1 expression, including patients who tested negative for PD-L1
    • Keytruda reduced risk of recurrence or death by over 40% vs. placebo as adjuvant therapy in resected, high-risk stage III melanoma
    • SU2C researchers find treatment strategy for stage I-III NSCLC
  • Drugs and Targets

    • FDA approves Tagrisso for front-line metastatic NSCLC with common EGFR mutations
    • FDA approves Opdivo and Yervoy for front-line advanced RCC
    • FDA approves Tavalisse for ITP
    • FDA issues guidance on investigational in vitro diagnostics in oncology trials
  • CTEP Protocols

    NCI Trials for April

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

Issue 15 - Apr 13, 2018
  • Sharpless: Expect a big boost to NCI’s RPG pool

    NCI’s Research Project Grant pool is likely to receive the largest increase in funding in 16 years, NCI Director Norman “Ned” Sharpless said at an NCI Town Hall meeting April 10.

    The increase is made possible by a $3 billion raise to NIH’s budget that translates into $275 million in new money for the institute in fiscal year 2018.

  • Whistleblower suit claims McKesson repackaged, sold cancer drug “overfill”

    A whistleblower lawsuit alleges that McKesson Corp. had been repackaging cancer drugs and charging the federal and state governments for “overfill,” extra drug that is routinely put into vials by manufacturers.

  • In Brief

    • Gradishar named chief of hematology and Oncology at Northwestern
    • Cole named chief of pediatric hematology/oncology at Rutgers
    • ACS CAN report examines patient barriers to cancer clinical trial enrollment
    • Woodcock, Shaw and Conway-Welch receive awards from Society for Women’s Health Research
    • Billings appointed chief medical officer at Natera
  • Funding Opportunities

    DOD Ovarian Cancer Research Program Publishes funding opportunities

    FY18 OCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

  • TCCL Logo

  • Trials and Tribulations

    Sales Revenues at the Potential Expense of Patient Safety: The Example of You&i TM

    Ibrutinib is a selective and irreversible inhibitor of Bruton’s tyrosine kinase (BTK) that entered phase 1 clinical trials in 2009 based on preclinical efficacy in models of B-cell malignancy and autoimmune disease.[1, 2] The initial phase 1 trial showed clear efficacy in a number of lymphoid malignancies at doses as low as 1.25 mg/kg/d. Furthermore, full receptor occupancy was demonstrated at 2.5 mg/kg/d. Despite these pharmacological and early clinical findings, development of ibrutinib continued at doses of 420 mg qd and 560 mg qd, levels 3-4 fold higher than suggested by the pharmacological data. In addition, the absorption of ibrutinib is enhanced by administration of food, which may explain why even the lowest dose showed efficacy in some patients.

  • Clinical Roundup

    • NCI study revises molecular classification for most common type of lymphoma
    • Updated ASTRO guideline for lung radiation recommends concurrent chemotherapy for some stage III patients
    • Keytruda monotherapy meets OS endpoint in phase III trial
    • Epacadostat plus Keytruda don’t meet PFS endpoint in phase III study in metastatic melanoma
    • Roswell Park, Ohio State researchers identify genes linked to blood and marrow transplant outcomes
  • Drugs and Targets

    • Rucaparib approved for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    • FDA finalizes guidances to accelerate development of Next Gen sequencing
    • Karyopharm’s Selinexor receive FDA Fast Track designation
    • MD Anderson, Nanobiotix to collaborate on preclinical research combining NBTXR3, nivolumab